Johnson & Johnson announces new ICOTYDE (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy
October 02, 2026
October 02, 2026
NEW BRUNSWICK, New Jersey, Oct. 2 [Category: BizHealth & Beauty] -- Johnson and Johnson posted the following news release:
* * *
Johnson & Johnson announces new ICOTYDE(r) (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy
*
Spring House, Pa. (October 2, 2026) - Johnson & Johnson (NYSE: JNJ) today announced new two-year data fr . . .
* * *
Johnson & Johnson announces new ICOTYDE(r) (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy
*
Spring House, Pa. (October 2, 2026) - Johnson & Johnson (NYSE: JNJ) today announced new two-year data fr . . .